VEGFA and hepatocellular carcinoma: Despite recent advances in the treatment of metastatic HCC, including the combination of checkpoint inhibitors with VEGF-targeting agents, prognosis remains poor, with median overall survival ranging between 12 and 20 months (15, 16).